J2184Inj, meropenem (b. braun)
Published CMS Medicare Part B payment-limit context for J2184, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$1.867
per 100 MG · Medicare Part B
Down 5.4%from $1.974 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$2.136$1.834
2024-Q4: $2.103; 2025-Q1: $2.074; 2025-Q2: $2.085; 2025-Q3: $2.075; 2025-Q4: $2.07; 2026-Q1: $2.009; 2026-Q2: $1.974; 2026-Q3: $1.867
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Meropenem ingredient family (FDA data as of August 20, 2026).
Meropenem
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Meropenem presentations
2 other CMS codesSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.